Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014

Diagnostic Microbiology and Infectious Disease

Volumn 85, Issue 4, 2016, Pages 459-465

  Lob, Sibylle H ^a   Nicolle, Lindsay E ^b   Hoban, Daryl J ^a   Kazmierczak, Krystyna M ^a   Badal, Robert E ^a   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Canada; ESBL; Escherichia coli; SMART; Susceptibility; United States; Urinary tract infection

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; COMMUNITY ACQUIRED INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEX RATIO; UNITED STATES; URINARY TRACT INFECTION; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PREVALENCE; URINARY TRACT INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CANADA; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84973531052     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.04.022     Document Type: Article

References (40)

1. Bouchillon, S.K., Hoban, D.J., Hawser, S.P., Badal, R.E., Cantón, R., Baquero, F., Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 54:7 (2010), 3043–3046.
2. Brusselaers, N., Vogelaers, D., Blot, S., The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care, 1, 2011, 47.
3. Castanheira, M., Mendes, R.E., Rhomberg, P.R., Jones, R.N., Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 14:3 (2008), 211–216, 10.1089/mdr. 2008.0827.
4. Castanheira, M., Farrell, S.E., Krause, K.M., Jones, R.N., Sader, H.S., Contemporary diversity of β-lactamases among enterobacteriaceae in the nine U.S. Census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58 (2014), 833–838.
5. Centers for Disease Control, Identifying Healthcare-associated infections (HAI) for NHSN surveillance. Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/2PSC_IdentifyingHAIs_NHSNcurrent.pdf, 2015 [Accessed on February 6, 2015].
6. Chen, L.F., Freeman, J.T., Nicholson, B., Keiger, A., Lancaster, S., Joyce, M., et al. Widespread Dissemination of CTX-M-15 Genotype Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae among Patients Presenting to Community Hospitals in the Southeastern United States. Antimicrob Agents Chemother 58:2 (2014), 1200–1202.
7. Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standards M7-A9, 9th ed., 2012, Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25, 2015, Clinical and Laboratory Standards Institute, Wayne, PA.
9. den Heijer, C.D., Penders, J., Donker, G.A., Bruggeman, C.A., Stobberingh, E.E., The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study. PLoS One, 8(3), 2013, e60497, 10.1371/journal.pone.0060497 [Epub 2013 Mar 29].
10. Denisuik, A.J., Lagacé-Wiens, P.R., Pitout, J.D., Mulvey, M.R., Simner, P.J., Tailor, F., et al. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007–11. J Antimicrob Chemother 68:Suppl. 1 (2013), i57–i65, 10.1093/jac/dkt027.
11. Dhillon, R., Clark, J., ESBLs: A clear and present danger?. Crit Care Res, 2012, 2012, 625170, 10.1155/2012/625170 [ http://www.hindawi.com/journals/ccrp/2012/625170/].
12. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. http://www.eucast.org, 2015.
13. Flamm, R.K., Sader, H.S., Farrell, D.J., Jones, R.N., Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80:3 (2014), 233–238, 10.1016/j.diagmicrobio.2014.07.005 [Epub 2014 Jul 24].
14. Fleming, V.H., White, B.P., Southwood, R., Resistance of Escherichia coli urinary isolates in ED-treated patients from a community hospital. Am J Emerg Med 32:8 (2014), 864–870, 10.1016/j.ajem.2014.04.033. Epub 2014.
15. Grigoryan, L., Zoorob, R., Wang, H., Trautner, B.W., Low Concordance With Guidelines for Treatment of Acute Cystitis in Primary Care. Open Forum Infect Dis, 2(4), 2015, ofv159.
16. Hawser, S., Hoban, D.J., Badal, R.E., Bouchillon, S.K., Biedenbach, D., Hackel, M., et al. Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011. J Chemother 27:2 (2015), 67–73, 10.1179/1973947814Y.0000000164.
17. Hoban, D.J., Lascols, C., Nicolle, L.E., Badal, R.E., Bouchillon, S., Hackel, M., et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis 74 (2012), 62–67.
18. Johnson, J.R., Johnston, B., Clabots, C., Kuskowski, M.A., Castanheira, M., Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 51 (2010), 286–294, 10.1086/653932.
19. Karlowsky, J.A., Lagacé-Wiens, P.R., Simner, P.J., DeCorby, M.R., Adam, H.J., Walkty, A., et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother 55:7 (2011), 3169–3175, 10.1128/AAC.00066-11 [Epub 2011 May 2].
20. Karlowsky, J.A., Adam, H.J., Desjardins, M., Lagacé-Wiens, P.R., Hoban, D.J., Zhanel, G.G., et al. Changes in fluoroquinolone resistance over 5 years (CANWARD 2007–11) in bacterial pathogens isolated in Canadian hospitals. J Antimicrob Chemother 68:Suppl. 1 (2013), i39–i46, 10.1093/jac/dkt025.
21. Kazmierczak, K.M., Lob, S.H., Hoban, D.J., Hackel, M.A., Badal, R.E., Bouchillon, S., Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008–2012. Results of the Study for Monitoring Antimicrobial Resistance Trends. Diagn Microbiol Infect Dis 82:3 (2015), 209–214, 10.1016/j.diagmicrobio.2015.03.025 [Epub 2015 Apr 9].
22. Kim, M., Lloyd, A., Condren, M., Miller, M.J., Beyond antibiotic selection: concordance with the IDSA guidelines for uncomplicated urinary tract infections. Infection 43:1 (2015), 89–94, 10.1007/s15010-014-0659-4.
23. Lagacé-Wiens, P.R., Simner, P.J., Forward, K.R., Tailor, F., Adam, H.J., Decorby, M., et al. Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada—results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis 69:3 (2011), 314–319, 10.1016/j.diagmicrobio.2010.10.027.
24. Lagacé-Wiens, P.R., Adam, H.J., Low, D.E., Blondeau, J.M., Baxter, M.R., Denisuik, A.J., et al. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007–11. J Antimicrob Chemother 68:Suppl. 1 (2013), i23–i29, 10.1093/jac/dkt023.
25. Lob, S.H., Badal, R.E., Hoban, D.J., et al. Epidemiology and Susceptibility of Pathogens from Hospital- and Community-Associated Urinary Tract Infection in Latin America: SMART 2010–2012. Abstract IDWeek 2013, abstr. 1596, 2013 [ https://idsa.confex.com/idsa/2013/webprogram/Paper41819.html].
26. Lob, S.H., Biedenbach, D.J., Badal, R.E., Kazmierczak, K.M., Sahm, D.F., Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013. J Glob Antimicrob Resist 3 (2015), 190–197.
27. Lob, S.H., Biedenbach, D., Hackel, M., Sahm, D., Leister-Tebbe, H., Comparison of Susceptibility of Enterobacteriaceae in European and North American ICU and Non-ICU Wards: TEST 2013. Abstract P0966, 25th ECCMID 2015, 2015.
28. Mathers, A.J., Peirano, G., Pitout, J.D., The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev 28:3 (2015), 565–591, 10.1128/CMR.00116-14.
29. Moayednia, R., Shokri, D., Mobasherizadeh, S., Baradaran, A., Fatemi, S.M., Merrikhi, A., Frequency assessment of β-lactamase enzymes in Escherichia coli and Klebsiella isolates in patients with urinary tract infection. J Res Med Sci 19:Suppl. 1 (2014), S41–S45.
30. Niranjan, V., Malini, A., Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. Indian J Med Res 139:6 (2014), 945–948.
31. Nordmann, P., Naas, T., Poirel, L., Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:10 (2011), 1791–1798.
32. Pitout, J.D., Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg?. Curr Pharm Des 19:2 (2013), 257–263.
33. Pitout, J.D., Nordmann, P., Laupland, K.B., Poirel, L., Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 56 (2005), 52–59.
34. Sader, H.S., Flamm, R.K., Jones, R.N., Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). J Chemother 26:3 (2014), 133–138, 10.1179/1973947813Y.0000000121 [Epub 2013 Dec 6].
35. Sader, H.S., Farrell, D.J., Flamm, R.K., Jones, R.N., Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78:4 (2014), 443–448.
36. Sanchez, G.V., Adams, S.J., Baird, A.M., Master, R.N., Clark, R.B., Bordon, J.M., Escherichia coli antimicrobial resistance increased faster among geriatric outpatients compared with adult outpatients in the USA, 2000–10. J Antimicrob Chemother 68:8 (2013), 1838–1841, 10.1093/jac/dkt110 [Epub 2013 Apr 4].
37. Sanchez, G.V., Babiker, A., Master, R.N., Luu, T., Mathur, A., Bordon, J., Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother 60:5 (2016), 2680–2683.
38. Spadafino, J.T., Cohen, B., Liu, J., Larson, E., Temporal trends and risk factors for extended-spectrum beta-lactamase-producing Escherichia coli in adults with catheter-associated urinary tract infections. Antimicrob Resist Infect Control, 3(1), 2014, 39, 10.1186/s13756-014-0039-y [eCollection 2014].
39. Tängdén, T., Giske, C.G., Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 277:5 (2015), 501–512, 10.1111/joim.12342 [Epub 2015 Jan 27].
40. Zilberberg, M.D., Shorr, A.F., Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol 34:9 (2013), 940–946, 10.1086/671740 [Epub 2013 Jul 25].